Integrated bioinformatics analysis and experimental validation identify BEX1 as a candidate biomarker in meningioma

Meningioma is the most common primary intracranial tumor, occurring at various sites where meninges attach and producing diverse clinical symptoms, imposing significant physical and psychological burdens on patients. Although a comprehensive treatment system is now established, research on drug therapy for meningioma has yet to show substantial progress. Therefore, we employed integrated transcriptomics technology to explore the pathogenesis of meningioma and identify candidate biomarker and potential regulator of meningioma biology. Subsequently, we performed cellular-level validation and exploratory single-cell analysis using single-cell transcriptome data from meningiomas through differential analysis, pseudo-time analysis, and cell communication analysis. In addition, qRT-PCR was performed to validate the expression level of BEX1 in meningioma cell lines. We found that the BEX1 gene is lowly expressed in meningioma tissue and tumor progenitor-like cells. Pseudotime analysis showed that BEX1 expression gradually decreased along the inferred pseudotime trajectory of tumor progenitor-like cells. Furthermore, qRT-PCR validation confirmed that BEX1 expression was significantly downregulated in meningioma cell lines compared with normal meningeal cells. Concurrently, BEX1 expression showed a decreasing trend along the inferred pseudotime trajectory of tumor progenitor-like cells. Tumor progenitor-like cells may be involved in predicted immune-related communication networks. BEX1 expression showed a decreasing trend across inferred cellular states along the pseudotime trajectory, suggesting a potential association with meningioma progression. These findings provide important clues for understanding the pathogenesis of meningioma and identify BEX1 as a candidate biomarker for further investigation. qRT-PCR validation further supported the relevance of BEX1 in meningioma biology.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-14
DOI
https://doi.org/10.1007/s12672-026-06306-0
Primary Topic
Meningioma and schwannoma management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrated bioinformatics analysis and experimental validation identify BEX1 as a candidate biomarker in meningioma

Junfeng Zhao, Yiming Han, Haining Luo, Yongxue Li
Discover Oncology
Meningioma and schwannoma management
article

Integrated bioinformatics analysis and experimental validation identify BEX1 as a candidate biomarker in meningioma

Junfeng Zhao, Yiming Han, Haining Luo, Yongxue Li
article en

Abstract

Meningioma is the most common primary intracranial tumor, occurring at various sites where meninges attach and producing diverse clinical symptoms, imposing significant physical and psychological burdens on patients. Although a comprehensive treatment system is now established, research on drug therapy for meningioma has yet to show substantial progress. Therefore, we employed integrated transcriptomics technology to explore the pathogenesis of meningioma and identify candidate biomarker and potential regulator of meningioma biology. Subsequently, we performed cellular-level validation and exploratory single-cell analysis using single-cell transcriptome data from meningiomas through differential analysis, pseudo-time analysis, and cell communication analysis. In addition, qRT-PCR was performed to validate the expression level of BEX1 in meningioma cell lines. We found that the BEX1 gene is lowly expressed in meningioma tissue and tumor progenitor-like cells. Pseudotime analysis showed that BEX1 expression gradually decreased along the inferred pseudotime trajectory of tumor progenitor-like cells. Furthermore, qRT-PCR validation confirmed that BEX1 expression was significantly downregulated in meningioma cell lines compared with normal meningeal cells. Concurrently, BEX1 expression showed a decreasing trend along the inferred pseudotime trajectory of tumor progenitor-like cells. Tumor progenitor-like cells may be involved in predicted immune-related communication networks. BEX1 expression showed a decreasing trend across inferred cellular states along the pseudotime trajectory, suggesting a potential association with meningioma progression. These findings provide important clues for understanding the pathogenesis of meningioma and identify BEX1 as a candidate biomarker for further investigation. qRT-PCR validation further supported the relevance of BEX1 in meningioma biology.

Discover Oncology
Sichuan University (CN), West China Hospital of Sichuan University (CN), The Central Hospital of Xiao gan (CN), Xiaogan First People's Hospital (CN), Affiliated Hospital of Qingdao University (CN), Huazhong University of Science and Technology (CN)
Meningioma and schwannoma management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon